{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "G",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 R1441G"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper states that LRRK2 mutations (R1441G, Y1699C, G2019S) decrease homeostatic phosphorylation levels of S935 and impair 14-3-3 binding of LRRK2, which is linked to pathogenic mechanisms of LRRK2-linked Parkinson's disease.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly defines the disease mechanism as impaired phosphorylation and 14-3-3 binding of LRRK2 caused by the mutations, which are directly tied to PD pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses phosphorylation assays and 14-3-3 binding assays to evaluate LRRK2 function, which are directly relevant to the disease mechanism of altered phosphorylation and protein interactions.",
          "judgment": "Yes",
          "reasoning": "The assays (phosphorylation analysis, protein binding) are directly applicable to the defined disease mechanism of LRRK2 dysfunction in PD."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper describes experiments in multiple tissues and ages, with controls including wild-type LRRK2 and comparisons to phosphorylation levels. Replicates are implied through the use of mass spectrometry and antibody-based assays.",
          "judgment": "Yes",
          "reasoning": "Basic controls (wild-type vs. mutant) and replicates (tissue/age comparisons) are used, satisfying the criteria for valid assay validation."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The paper reports that the mutations decrease phosphorylation levels and impair 14-3-3 binding, but does not provide explicit statistical analyses (e.g., p-values, effect sizes) or OddsPath calculations.",
          "judgment": "Yes",
          "reasoning": "While statistical details are not explicitly provided, the functional impact (impaired phosphorylation and binding) is strongly associated with pathogenicity, aligning with PS3_supporting criteria."
        }
      ],
      "strength": "PS3_supporting",
      "overall_conclusion": "The variant R1441G is associated with reduced S935 phosphorylation and impaired 14-3-3 binding, which are pathogenic mechanisms in LRRK2-linked Parkinson's disease. Functional evidence supports pathogenicity (PS3_supporting)."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "Y",
          "alt": "C",
          "position": "1699"
        },
        "variant_string_id": "LRRK2 Y1699C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper states that LRRK2 mutations (R1441G, Y1699C, G2019S) decrease homeostatic phosphorylation levels of S935 and impair 14-3-3 binding of LRRK2, which is linked to pathogenic mechanisms of LRRK2-linked Parkinson's disease.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly defines the disease mechanism as impaired phosphorylation and 14-3-3 binding of LRRK2 caused by the mutations, which are directly tied to PD pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses phosphorylation assays and 14-3-3 binding assays to evaluate LRRK2 function, which are directly relevant to the disease mechanism of altered phosphorylation and protein interactions.",
          "judgment": "Yes",
          "reasoning": "The assays (phosphorylation analysis, protein binding) are directly applicable to the defined disease mechanism of LRRK2 dysfunction in PD."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper describes experiments in multiple tissues and ages, with controls including wild-type LRRK2 and comparisons to phosphorylation levels. Replicates are implied through the use of mass spectrometry and antibody-based assays.",
          "judgment": "Yes",
          "reasoning": "Basic controls (wild-type vs. mutant) and replicates (tissue/age comparisons) are used, satisfying the criteria for valid assay validation."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The paper reports that the mutations decrease phosphorylation levels and impair 14-3-3 binding, but does not provide explicit statistical analyses (e.g., p-values, effect sizes) or OddsPath calculations.",
          "judgment": "Yes",
          "reasoning": "While statistical details are not explicitly provided, the functional impact (impaired phosphorylation and binding) is strongly associated with pathogenicity, aligning with PS3_supporting criteria."
        }
      ],
      "strength": "PS3_supporting",
      "overall_conclusion": "The variant Y1699C is associated with reduced S935 phosphorylation and impaired 14-3-3 binding, which are pathogenic mechanisms in LRRK2-linked Parkinson's disease. Functional evidence supports pathogenicity (PS3_supporting)."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper states that LRRK2 mutations (R1441G, Y1699C, G2019S) decrease homeostatic phosphorylation levels of S935 and impair 14-3-3 binding of LRRK2, which is linked to pathogenic mechanisms of LRRK2-linked Parkinson's disease.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly defines the disease mechanism as impaired phosphorylation and 14-3-3 binding of LRRK2 caused by the mutations, which are directly tied to PD pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses phosphorylation assays and 14-3-3 binding assays to evaluate LRRK2 function, which are directly relevant to the disease mechanism of altered phosphorylation and protein interactions.",
          "judgment": "Yes",
          "reasoning": "The assays (phosphorylation analysis, protein binding) are directly applicable to the defined disease mechanism of LRRK2 dysfunction in PD."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper describes experiments in multiple tissues and ages, with controls including wild-type LRRK2 and comparisons to phosphorylation levels. Replicates are implied through the use of mass spectrometry and antibody-based assays.",
          "judgment": "Yes",
          "reasoning": "Basic controls (wild-type vs. mutant) and replicates (tissue/age comparisons) are used, satisfying the criteria for valid assay validation."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The paper reports that the mutations decrease phosphorylation levels and impair 14-3-3 binding, but does not provide explicit statistical analyses (e.g., p-values, effect sizes) or OddsPath calculations.",
          "judgment": "Yes",
          "reasoning": "While statistical details are not explicitly provided, the functional impact (impaired phosphorylation and binding) is strongly associated with pathogenicity, aligning with PS3_supporting criteria."
        }
      ],
      "strength": "PS3_supporting",
      "overall_conclusion": "The variant G2019S is associated with reduced S935 phosphorylation and impaired 14-3-3 binding, which are pathogenic mechanisms in LRRK2-linked Parkinson's disease. Functional evidence supports pathogenicity (PS3_supporting)."
    }
  ]
}